Leading R&D Ventures and Digital Biology at IFF, building a global portfolio of TechBio platforms from discovery through commercialization. I focus on scaling AI‑enabled biology where industrial reality matters, linking prediction to manufacturing to deliver revenue acceleration, margin expansion, and access to novel molecules previously impossible to produce at scale.I lead the evolution of IFF’s Lab‑in‑a‑Loop platform, integrating AI, protein engineering, and bioprocessing to translate breakthrough science into durable businesses. My role spans platform strategy, external partnerships, and strategic M&A, acquiring critical AI/ML, synthetic biology, talent, and manufacturing capabilities. Core thesis: biology only scales when economics, sustainability, and user value align.Previously, I led global enzyme, strain, and bioprocess programs across four continents, delivering 40+ technology transfers and 13 commercial products, including one of the highest‑tonnage engineered enzymes ever commercialized. I also led the enzyme platform for the $225M DuPont cellulosic ethanol FOAK biorefinery.I advise startups, investors, and U.S. government and National Labs. PhD in Biochemical Engineering (UC Berkeley), Harvard Business School alumnus, 36 patents, JBEI Board member, and UC Berkeley guest lecturer.